How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

61,345 results for

Electrocardiogram

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

23281. Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

-tests Assess the Safety of OMS643762 [ Time Frame: 28 days ] Safety as assessed by ECG Assess the Safety of OMS643762 [ Time Frame: 28 days ] Safety as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Secondary Outcome Measures : Motor function [ Time Frame: Pre-dose and day 15 and 28 post-dose ] Change from baseline in the UHDRS - Total Motor Score Motor function [ Time Frame: Pre-dose and day 15 and 28 post-dose ] Change from baseline in the Speeded Tapping Test score Cognition [ Time (...) include spermicide in combination with a barrier method, or subjects' female partner is willing to use medically acceptable methods of birth control. Have normal clinical laboratory test results and ECG, or results with minor deviations, which are not considered to be clinically significant by the investigator. Exclusion Criteria: Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders other than HD which

2014 Clinical Trials

23282. RCT of Methotrexate Added to Treatment As Usual in Schizophrenia

trial by scrutinising the patients' past medical history, most recent blood results, electrocardiograms, as well as any physical tests that have been performed on the patient. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02074319 Locations Layout

2014 Clinical Trials

23283. Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavanceâ„¢ (RPX2014/RPX7009) in Healthy Adult Subjects

) and weight between 55.0 and 100.0 kg (inclusive) at the time of screening. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, electrocardiograms (ECGs), physical examination) as deemed by the PI. Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day 1. Voluntarily consent to participate in the study. Exclusion Criteria: History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal

2014 Clinical Trials

23284. Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

the 6th injection ] blood chemistries test within 3 days after the 6th injection electrocardiogram [ Time Frame: baseline ] electrocardiogram test within 3 days before first vaccination electrocardiogram [ Time Frame: within 3 days after the second injection ] electrocardiogram test within 3 days after the second injection electrocardiogram [ Time Frame: within 3 days after the 6th injection ] electrocardiogram test within 3 days after the 6th injection progression-free survival rate of six month

2014 Clinical Trials

23285. A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

-PD-1 therapy, must not have worsening of Eastern Cooperative Oncology Group (ECOG) performance status due to their disease progression, and cannot have new CNS lesion. Patients must also meet the lactic acid dehydrogenase (LDH) or ECOG status. No tumor size criteria are used in Part 2SA. ≥ 18 years of age. Life expectancy of ≥ 6 months per the investigator. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. ECG without evidence of clinically significant arrhythmia or ischemia

2014 Clinical Trials

23286. Hospital Wearable Defibrillator Inpatient Study

of sudden cardiac arrest during the hospitalization period, wearing the HWD1000 hospital wearable defibrillator in order to evaluate caregiver and patient interactions with the device. In addition, ECG signal quality will be reviewed to confirm the HWD1000 safety profile. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 59 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Basic (...) of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise. [ Time Frame: 24 hours or longer ] The amount of time that the HWD1000 is unable to monitor the subject's rhythm status is the primary safety measure. The specific goals are that average monitoring will be inhibited by noise no greater than 2% of the time worn (at least 24 hours) and monitoring using single lead analysis will be no greater than 5% of the time worn (at least 24 hours). Eligibility Criteria Go to Information from

2014 Clinical Trials

23287. A Study to Investigate the Phototoxic Potential of Faldaprevir

information Ages Eligible for Study: 18 Years to 55 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion criteria: Health male and female subjects with no clinically significant abnormality (according to the Investigator's assessment) identified from a complete medical history, physical examination, whole body skin assessment, 12-lead ECG, vital signs and clinical laboratory tests. In particular, there should be no evidence of abnormal photosensitivity Sun

2014 Clinical Trials

23288. Mitochondrial nt3243 A>G Mutation in Taiwan

impairment, myopathy, electrocardiogram abnormality, chronic progressive external ophthalmoplegia), relevant family history, treatment, and outcome will be recorded. Full MELAS phenotype was defined as the presence of focal central nervous system events, either seizures, strokes, or both. Genetic analysis. Genomic DNA was extracted from peripheral blood leukocytes using the Puregene DNA purification kit (Gentra Systems, Minneapolis, Minnesota, USA). Polymerase chain reaction (PCR) for mitochondrial DNA

2014 Clinical Trials

23289. Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention

questionnaires will be done at each visit. Standard of care blood work, chest x-ray, and ECG will be done in the AAD arm depending on the AAD chosen as treatment. ICD programming will be standardized for all subjects. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Antiarrhythmic Therapy (...) for eligibility information Ages Eligible for Study: 18 Years to 85 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: ≥ 18 and ≤ 85 years old Able to provide informed consent AICD implanted for primary prophylaxis against sudden cardiac death AICD implanted for secondary prophylaxis against spontaneous or inducible sustained VT without any reversible causes CAD with prior myocardial infarction (>60 days prior to enrollment) AICD or ECG

2014 Clinical Trials

23290. SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

is ≥ 18 years old. The patient has an ECOG performance score (PS) of 0-2. The patient has adequate baseline organ function, including cardiac, renal, and hepatic function: Left ventricular ejection fraction (LVEF) ≥ 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG Serum creatinine ≤ 1.5 mg/dl Serum albumin ≥ 3.0 g/dl Bilirubin ≤ 1.5 mg/dl AST and ALT ≤ 2.5 times the upper limit of normal (ULN) If the patient (...) that is either previously untreated or is persistent/recurrent following prior treatment for BPDCN. The patient is ≥ 18 years old. The patient has an ECOG performance score (PS) of 0-2. The patient has adequate baseline organ function, including cardiac, renal, and hepatic function: Left ventricular ejection fraction (LVEF) ≥ 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG Serum creatinine ≤ 1.5 mg/dl Serum albumin

2014 Clinical Trials

23291. A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

, lipid panel and lymphocyte subpopulation. Safety and tolerability as assessed by vital signs [ Time Frame: up to 18 months ] Vital signs to be measured includes blood pressure, pulse rate and temperature. Safety and tolerability as assessed by 12-lead electrocardiograms (ECGs) [ Time Frame: up to 18 months ] Secondary Outcome Measures : Composite of pharmacokinetics of ASP8273 concentration and its metabolites (plasma): Cmax, tmax, AUClast, AUCinf, t1/2, CL/F, and Vz/F [ Time Frame: Cycle 0: Dose

2014 Clinical Trials

23292. NON INVASIVE MAPPING OF ATRIAL FIBRILLATION

by (Responsible Party): Pr Sébastien Knecht, Brugmann University Hospital Study Details Study Description Go to Brief Summary: RATIONALE / CONTEXT The ECG records the electrical activity propagating along cardiac cells (from the atria to the ventricles). The standard 12 ECG leads placed on the chest measure the global activation of the heart and do not have the ability to detect small-scale disturbances or to pinpoint ectopic activity. By the 1960s, multiple electrodes were placed around the chest to try (...) to understand the complexity of the distribution of electrical activity in relation to the single cardiothoracic geometry of each individual. The safety of this method is similar to the ECG but its superiority has been demonstrated by the detection of anomalies imperceptible to the standard ECG. The accuracy of the technique in localizing rhythm disturbances is on the order of 5 mm. OBJECTIVES Main objective: To evaluate the utility of noninvasive mapping during persistent AF electrophysiology procedure

2014 Clinical Trials

23293. Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

, musculoskeletal, and neurological systems. Clinical importance of physical examination changes was determined by the investigator. Number of Participants With Clinically Significant Treatment-Emergent Electrocardiogram (ECG) Findings [ Time Frame: Baseline up to 30 days post last dose on Day 29 ] Maximum absolute values and increases from baseline were summarized for PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset (...) of ventricular depolarization), QRS complex (time from Q wave to the end of S wave, corresponding to ventricle depolarization), and QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula). Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval >=300 msec; (2) QRS complex >=200 msec; (3) QTcF interval: 450 to <480 msec; (4) QTcF interval: 480 to <500 msec; (5

2014 Clinical Trials

23294. Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

that could interfere with the oral absorption or tolerance of alisertib. Examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease. Myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. If for some reason an electrocardiogram

2014 Clinical Trials

23295. Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

(whichever is the longer of the two). As for the patients who has evaluable ECG data at Visit 1, QT interval corrected (Fridericia) for heart rate (QTc[F])>=450 milliseconds (msec). The QT interval corrected for heart rate (QTc) should be based on averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period. As for the patients who don't has evaluable ECG data at Visit 1, if the patient has known prolonged QTc>=450 msec (any correction is valid), the patient (...) infection and cannot be identified to be negative for RS virus antigen during run-in period. A patient who has no evaluable ECG data during the run-in period. As for the patients who has evaluable ECG data during the run-in period, QTc(F) >=450 msec. The QTc should be based on averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period. A patient who has not been able to appropriately record patient diary or inhale FP appropriately during the run-in period

2014 Clinical Trials

23296. Treatment of Atrial Fibrillation in Patients by Pulmonary Vein Isolation, Renal Artery Denervation or Both.

loop recorders for cardiac rhythm monitoring, this data will be used for the study. The other patients will undergo Holter ECG monitoring at regular intervals during follow-up (at 3, 6 and 12 months after the interventional treatment). During follow-up, the first 3 months after the interventional treatment will be a blanking period, as is common in the ablative therapy of AF (ablations points need to heal, and paroxysms of AF in this period are not associated with therapy failure). Study Design Go

2014 Clinical Trials

23297. Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans

upside down Other Name: NEMOS®, Cerbomed, Erlangen, Germany Outcome Measures Go to Primary Outcome Measures : fear response [ Time Frame: 3 test days ] startle blink EMG skin conductance response ECG respiration self-reports Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your

2014 Clinical Trials

23298. CyclASol® Phase 1 Study

and ECGs will be performed, and blood samples will be analyzed for Cyclosporine A and Placebo (vehicle). Condition or disease Intervention/treatment Phase Healthy Drug: CyclASol® Drug: Placebo (vehicle) Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 18 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose

2014 Clinical Trials

23299. Haemodynamic Effects During Anorectal Surgery: a Comparison of the Jack -Knife and Lithotomy Position

standardized by protocol. All patients were premedicated with oral diazepam 5mg and diclofenac 100mg 60min before operation. After arrival in the operating theater peripheral vein 18 or 20G catheter was inserted, infusion therapy were started with crystalloid 5-7ml/kg/hour. Standard monitoring was used, including noninvasive arterial blood pressure (BP), electrocardiography (ECG), heart rate, peripheral oxygenation. Circulatory changes were recorded impedance device. 2 single-neck sensors connected

2014 Clinical Trials

23300. Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

pressure and radial pulse rate), blood and urine laboratory panel, and ECG Treatment discontinuation due to AEs Suicidality as assessed by the C-SSRS score Change from Baseline to EOT in sleep as assessed by the sleep subscale of the CDRS-R. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 200 participants Allocation: Randomized Intervention Model: Single Group Assignment Masking: Quadruple (Participant, Care Provider (...) conditions or clinically important laboratory abnormalities have ECG or physical examination abnormality at screening have body weight less than the 3rd percentile or greater than the 97th percentile for age. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>